1. Home
  2. JSPR

as of 11-16-2026 9:35am EST

$13.58
+$0.05
+0.37%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.

Founded: 2018 Country:
United States
United States
Employees: N/A City: REDWOOD CITY
Market Cap: 26.3M IPO Year: 2019
Target Price: N/A AVG Volume (30 days): 321.1K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: annual
EPS: -0.14 EPS Growth: 19.22
52 Week Low/High: $0.32 - $17.03 Next Earning Date: 11-27-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): -100.00%
P/E Ratio: -96.64 Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

AI-Powered JSPR Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 20 hours ago

AI Recommendation

sell
Model Precision: 20.83%
20.83%
AI Precision

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K BUY

Nov 16, 2026 · 100% conf.

AI Prediction BUY

1D

+1.92%

$13.79

5D

+8.43%

$14.67

20D

-0.66%

$13.44

Price: $13.53 Prob +5D: 100% AUC: 1.000
0001213900-26-120141

EX-99.1

2 ea031213401ex99-1.htm

PRESS RELEASE, DATED NOVEMBER 16, 2026

Exhibit 99.1

Jasper Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

REDWOOD

CITY, Calif., November 16, 2026 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today reported results for the fiscal quarter ended September 30, 2026, and provided a corporate update.

“We have made progress advancing our development programs in recent months following our acquisition of Kira Pharmaceuticals, highlighted by the recent completion of enrollment in the first cohort of our Phase 2 renal basket study evaluating vensobafusp alfa (KP104) in patients with IgA nephropathy (IgAN),” said Jeet Mahal, President and Chief Executive Officer of Jasper. “In addition, we enrolled the first patient with immune complex membranoproliferative glomerulonephritis (IC-MPGN) in the renal basket study and commenced an expansion cohort in patients with focal segmental glomerulosclerosis (FSGS), with the first patient expected to be dosed in the first quarter of 2027. We believe that the bifunctional ability of vensobafusp alfa to inhibit both the alternative and terminal complement pathways may provide the potential for differentiated onset and efficacy in complement driven diseases, and we look forward to presenting interim data from the IgAN cohort in the fourth quarter of 2026 and additional updates from our pipeline programs in 2027.”

Third Quarter 2026 and Recent Highlights

●Completed enrollment in first cohort of Phase 2 renal basket study evaluating vensobafusp alfa in IgA nephropathy.

○Jasper expects to report interim IgAN data from Stage 1 of the renal basket study in the fourth quarter of 2026 and updated data in the first quarter of 2027.

●Announced the opening of an expansion cohort in the renal basket study evaluating vensobafusp alfa in patients with FSGS, with first patients expected to be dosed in first quarter 2027.

●Commenced patient enrollment in the C3 glomerulopathy (C3G)/IC-MPGN cohort of the renal basket study.

○First IC-MPGN patient dosed.

○IC-MPGN

is a complement-mediated glomerulonephritis characterized by immune complex deposition, complement

activation, and downstream alternative pathway amplification. Given the overlap with C3G in complement biology, IC-MPGN is being evaluated together with C3G in a rare complement-mediated kidney disease cohort

●Jasper is completing a Phase 1/2 case control study evaluating briquilimab as a conditioning agent for SCID patients receiving hematopoietic stem cell transplant.

○The company expects to present initial data from the study in the fourth quarter of 2026.

●In July 2026, Jasper completed the acquisition of Kira Pharmaceuticals (“Kira”), a Cayman limited company that was engaged in the design of complement therapies to treat immune-mediated diseases, in an all-stock transaction.

○Concurrently with the acquisition, Jasper entered into a securities purchase agreement for the sale of non-voting convertible preferred stock (the “Preferred Stock”) in a private placement co-led by Affinity Asset Advisors, LLC and Ikarian Capital LLC with participation from other life science investors. The private placement closed on July 20, 2026 and resulted in gross proceeds of approximately $132.0 million.

●Announced the appointment of Lisa Pitt, Pharm.D., M.S.J. as Senior Vice President, Regulatory Affairs and Shiguang Liu, M.D., Ph.D. as Vice President, Clinical Development.

●Commenced an offer to purchase any and all of its outstanding warrants that were issued in its underwritten public offering on September 18, 2025. The purchase price was $9.72 in cash per warrant (post-reverse stock split).

○The Company has been advised that a total of 283,689 Warrants (post-reverse stock split) were properly tendered, which represents an aggregate cash payment of approximately $2.8 million. Following completion of the offer, 127,834 Warrants remain outstanding.

●In November 2026, Jasper effected a 1-for-30 reverse stock split (“Reverse Split”) of the Company’s common stock. Following the Reverse Split, there were approximately 1.1m shares of common stock issued and outstanding.

Third Quarter Fiscal 2026 Financial Results

●Cash and cash equivalents as of September 30, 2026, totaled $135.3 million.

●Research and development expense for the three months ended September 30, 2026, was $8.3 million.

●General and administrative expense for the three months ended September 30, 2026, was $6.4 million.

About Jasper

Jasper is a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases. The company is advancing a pipeline of medicines including vensobafusp alfa, briquilimab, and KP701. Vensobafusp alfa is a potential best-in-class dual-complement inhib

2026
Q2

Q2 2026 Earnings

8-K SELL

Aug 14, 2026 · 100% conf.

AI Prediction SELL

1D

-3.28%

$0.76

Act: +6.59%

5D

-9.53%

$0.71

20D

-18.96%

$0.64

Price: $0.79 Prob +5D: 0% AUC: 1.000
0001213900-26-090055

EX-99.1

2 ea030204901ex99-1.htm

PRESS RELEASE, DATED AUGUST 14, 2026

Exhibit 99.1

Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio of clinical stage assets focused on immunologically-driven disorders

Completed a concurrent PIPE financing raising $132 million in gross proceeds

REDWOOD CITY, Calif., August 14, 2026 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today reported results for the fiscal quarter ended June 30, 2026, and provided a corporate update.

“We are excited to unite Jasper Therapeutics and Kira Pharmaceuticals to advance our shared mission of developing a differentiated portfolio of innovative therapies for patients with significant immune-mediated diseases. Supported by our recent $132 million financing led by leading life sciences investors, we believe that we have sufficient capital to fund planned operations through the second half of 2028. We plan to advance development of our lead asset KP-104, a novel dual inhibitor of the complement cascade, in multiple indications, progress briquilimab towards a potential BLA, and to commence first in human studies for KP-701,” said Jeet Mahal, President and Chief Executive Officer of Jasper. “The combined company now has access to significant resources in the United States and China, which we believe will allow us to rapidly advance our portfolio across multiple diseases of unmet need.”

Corporate Updates for Second Quarter 2026 and Recent Weeks

●On July 16, 2026, Jasper completed the acquisition of Kira Pharmaceuticals (“Kira”), a former Cayman limited company that was engaged in the design of complement therapies to treat immune-mediated diseases, in an all-stock transaction.

●Concurrently with the acquisition, Jasper entered into a securities purchase agreement for the sale of non-voting convertible preferred stock (the “Preferred Stock”) in a private placement co-led by Affinity Asset Advisors, LLC and Ikarian Capital LLC with participation from other leading life science investors. The private placement resulted in total gross proceeds of approximately $132 million.

●The combined company is focused on advancing its consolidated pipeline of potential best-in-class innovative therapies for immunologically-driven disorders, including:

oKP-104 (Vensobafusp alfa), a Phase 2/3 ready, potentially best-in-disease, bifunctional biologic targeting

both the alternative and terminal pathways within the complement cascade for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and high unmet need nephrology disorders. KP-104 is currently being evaluated in a Phase 2 basket trial in rare renal indications and interim data from Stage 1 of the trial is expected in the fourth quarter of 2026. Based on previous, positive results in treatment-naïve PNH, the combined company is also planning for an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) and plans to announce next steps for development in PNH in the first half of 2027;

oBriquilimab, a late-stage, potentially best-in-class anti-KIT antibody with broad therapeutic utility across multiple transplant and immunologic indications. Based on positive, long-term data generated in SCID, the combined company is progressing its efforts towards a pre-BLA meeting with the FDA and expects to announce next steps in the first quarter of 2027; and

oKP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders. The combined company expects to file a clinical trial application (CTA) and/or an investigational new drug (IND) for Phase 1 evaluation in the first quarter of 2027.

Second Quarter Fiscal 2026 Financial Results

●Cash and cash equivalents as of June 30, 2026, totaled $7.3 million.

●Research and development expense for the three months ended June 30, 2026, was $5.1 million.

●General and administrative expense for the three months ended June 30, 2026, was $4.1 million.

●Jasper reported a net loss of $2.8 million, or basic and diluted net loss per share attributable to common stockholders of $0.10 for the three months ended June 30, 2026.

About Jasper

The combined company is a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases. The combined company is advancing a pipeline of medicines including KP-104, briquilimab, and KP-701. KP-104 is a potential best-in-class dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other high unmet need nephrology disorders. Briquilimab is an anti-KIT antibody which has demonstrated positive clinical results both as a conditi

2026
Q1

Q1 2026 Earnings

8-K SELL

May 14, 2026 · 100% conf.

AI Prediction SELL

1D

-2.18%

$0.94

Act: -12.05%

5D

-9.59%

$0.87

Act: -9.01%

20D

-14.79%

$0.82

Act: -52.28%

Price: $0.96 Prob +5D: 0% AUC: 1.000
0001213900-26-056596

EX-99.1

2 ea029079201ex99-1.htm

PRESS RELEASE, DATED MAY 14, 2026

Exhibit 99.1

Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

REDWOOD CITY, Calif., May 14, 2026 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended March 31, 2026 and provided a corporate update.

“In recent months, we have continued to advance the briquilimab development program in CSU.” said Jeet Mahal, President and Chief Executive Officer of Jasper. “Following our positive clinical data update in January, we have conducted an analysis of the full data package from BEACON, SPOTLIGHT and the open-label extension study to drive the selection of two active dosing regimens to evaluate in our Phase 2b study. In parallel we have also updated and refiled the Phase 2b protocol with the FDA as we work to secure additional funding to enable commencement of the study in the second half of this year as planned.”

Highlights for First Quarter 2025 and Recent Weeks

●Refiled an updated Phase 2b protocol with the FDA for the planned Phase 2b study of briquilimab in CSU.

●Jeet Mahal appointed as Chief Executive Officer to lead next phase of clinical growth.

●Reported positive updated data from briquilimab studies in chronic spontaneous urticaria in January 2026:

o67% of additional patients (n=6) enrolled in the BEACON study given an initial dose of 240mg briquilimab followed by 180mg every 8 weeks achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points

o75% of CSU participants (n=36) enrolled in the open label extension dosed with 180mg briquilimab every 8 weeks achieved a complete response or well controlled disease at 12 weeks

oWith a median duration of follow up of more than 200 days on 63 participants in the open label extension study, KIT related AEs were low in frequency and predominantly low-grade events that resolved while on study

First Quarter Fiscal 2026 Financial Results

●Cash and cash equivalents as of March 31, 2026, totaled $14.1 million.

●Research and development expense for the three months ended March 31, 2026, was $5.8 million.

●General and administrative expense for the three months ended March 31, 2026, was $5.1 million.

●Jasper reported a net loss of $1.2 million, or basic and diluted net loss per share attributable to common stockholders of $0.04 for the three months ended March 31, 2026.

About Jasper

Jasper is a clinical-stage biotechnology company

focused on developing briquilimab as a therapeutic for chronic mast cell diseases. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the KIT receptor, thereby inhibiting signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of the inflammatory response in mast cell driven diseases such as chronic urticaria and asthma. Jasper is currently evaluating briquilimab as a treatment in patients with CSU, CIndU and asthma. Briquilimab has a demonstrated efficacy and safety profile in patients and healthy volunteers, with positive clinical outcomes in CSU, CIndU and allergic asthma. For more information, please visit us at www.jaspertx.com.

Forward-Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab’s potential, including with respect to its potential in mast cell driven diseases such as CSU, CIndU and asthma; Jasper’s continued advancement of its briquilimab development program in CSU; Jasper’s Phase 2b study in CSU, including the planned commencement thereof and the selection of dosing regimes; and Jasper’s work to secure additional funding for its Phase 2b study in CSU. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as,

Share on Social Networks: